Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 405% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- Loss-making — negative ROE of -101.8%
- Revenue growing at 8% annually
Amneal Pharmaceuticals, Inc. (AMRX) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $3.8 billion . Key value metrics: P/E ratio 101.8, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Amneal Pharmaceuticals, Inc. — Fundamental Analysis Summary
Amneal Pharmaceuticals, Inc. (AMRX) is currently trading 405% above its Graham Number of $2.36, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 101.8x.
On financial health, AMRX shows a moderate Piotroski F-Score of 6/9, and negative return on equity of -101.8% (sector average: -19.8%).
StockPik's composite Value Score for AMRX is 61/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
AMRX reports a moderate gross margin of 37.3% (sector average: 33.5%) and a solid operating margin of 12.8%.
AMRX shows revenue growing at 8% year-over-year, with earnings growing at 162%.